solute carrier family 36 member 3Genealiases: PAT3 · TRAMD2 · tramdorin2
Q-omics provides the consensus-scored SLC36A3 profile across patient tissues and cancer cell-line models. SLC36A3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SLC36A3 is differentially expressed in 2, with the highest sampling consensus in PAAD. Additionally, SLC36A3 RNA expression shows 6,539 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, PAAD, and STAD as cancer lineages where SLC36A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC36A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC36A3 survival associations across molecular data types. SLC36A3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC36A3 RNA expression–survival associations across cancer types. High SLC36A3 expression shows unfavorable associations in KICH, LIHC, LUAD and READ, but favorable associations in PRAD and UVM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SLC36A3 RNA expression.
This table summarizes SLC36A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for SLC36A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC36A3 shows higher tumor expression in PAAD and KIRC. The PAAD box plot shows higher SLC36A3 RNA expression in tumor versus normal tissue (log2 FC = +0.025, t-test p = .037).
This table shows molecular features associated with SLC36A3 in patient tissues and cancer cell lines. In patient samples, SLC36A3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC36A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
